Bianca Weinstock-Guttman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/828888/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intramuscular interferon betaâ€1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 1996, 39, 285-294.	5.3	2,365
2	Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 911-923.	27.0	1,249
3	Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society, 2006, 12, 549-58.	1.8	633
4	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of the Neurological Sciences, 2005, 231, 29-34.	0.6	446
5	Thalamic atrophy and cognition in multiple sclerosis. Neurology, 2007, 69, 1213-1223.	1.1	446
6	Prediction of Neuropsychological Impairment in Multiple Sclerosis. Archives of Neurology, 2004, 61, 226.	4.5	351
7	Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis. Annals of Neurology, 1998, 43, 79-87.	5.3	346
8	The incidence and significance of anti-natalizumab antibodies. Neurology, 2007, 69, 1391-1403.	1.1	312
9	Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology, 1998, 50, 1266-1272.	1.1	309
10	Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Multiple Sclerosis Journal, 2007, 13, 52-57.	3.0	297
11	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	10.2	292
12	Neocortical Atrophy, Third Ventricular Width, and Cognitive Dysfunction in Multiple Sclerosis. Archives of Neurology, 2006, 63, 1301.	4.5	282
13	Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 393-396.	3.0	281
14	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology, 2006, 66, 685-692.	1.1	276
15	Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology, 2004, 63, 2039-2045.	1.1	275
16	Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. Journal of Neurology, 2012, 259, 139-146.	3.6	274
17	Reliable screening for neuropsychological impairment in multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 675-678.	3.0	234
18	Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Multiple Sclerosis Journal, 2010, 16, 228-237.	3.0	224

#	Article	IF	CITATIONS
19	The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis. Annals of Neurology, 1995, 37, 7-15.	5.3	214
20	Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clinical Neuropsychologist, 2010, 24, 1131-1145.	2.3	205
21	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 846-855.	27.0	201
22	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.6	193
23	Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 2011, 77, 138-144.	1.1	189
24	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. Journal of Neuroinflammation, 2011, 8, 127.	7.2	186
25	Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Multiple Sclerosis Journal, 2009, 15, 1077-1084.	3.0	185
26	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	10.1	185
27	Low fat dietary intervention with ω-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 397-404.	2.2	183
28	Management of Multiple Sclerosis. New England Journal of Medicine, 1997, 337, 1604-1611.	27.0	179
29	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. NeuroImage, 2012, 59, 331-339.	4.2	176
30	Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 201-206.	1.9	174
31	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	5.3	172
32	Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease). Archives of Neurology, 2006, 63, 957.	4.5	167
33	MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498.	1.1	166
34	Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Multiple Sclerosis Journal, 2008, 14, 940-946.	3.0	163
35	The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. NeuroImage, 2005, 26, 1068-1077.	4.2	161
36	The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society, 2010, 16, 6-16.	1.8	159

#	Article	IF	CITATIONS
37	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis. Neurology, 2014, 82, 1083-1092.	1.1	159
38	Diversity and plasticity of self recognition during the development of multiple sclerosis Journal of Clinical Investigation, 1997, 99, 1682-1690.	8.2	155
39	Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 437-444.	3.0	147
40	Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. Journal of the Neurological Sciences, 2008, 268, 12-17.	0.6	147
41	Common viruses associated with lower pediatric multiple sclerosis risk. Neurology, 2011, 76, 1989-1995.	1.1	141
42	Unemployment in multiple sclerosis: the contribution of personality and disease. Multiple Sclerosis Journal, 2012, 18, 647-653.	3.0	138
43	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology, 2017, 88, 1623-1629.	1.1	138
44	Gut microbiota composition and relapse risk in pediatric MS: A pilot study. Journal of the Neurological Sciences, 2016, 363, 153-157.	0.6	137
45	Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain, 2009, 132, 3392-3400.	7.6	130
46	Aging and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 717-725.	3.0	128
47	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	2.8	126
48	Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology, 2011, 76, 1500-1507.	1.1	122
49	Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology, 2001, 56, 1324-1330.	1.1	121
50	Upper and Lower Extremity Motor Function and Cognitive Impairment in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2011, 17, 643-653.	1.8	121
51	Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis. Journal of Child Neurology, 2013, 28, 102-107.	1.4	121
52	Extended interval dosing of natalizumab in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 885-889.	1.9	118
53	Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology, 2009, 73, 504-510.	1.1	116
54	Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a032003.	6.2	116

#	Article	IF	CITATIONS
55	Lipid profiles are associated with lesion formation over 24â€months in interferon-β treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	1.9	114
56	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to <i>in vivo</i> imaging. Neural Regeneration Research, 2019, 14, 373.	3.0	114
57	Genomic Effects of IFN-β in Multiple Sclerosis Patients. Journal of Immunology, 2003, 171, 2694-2702.	0.8	113
58	Multiple sclerosis characteristics in A frican A merican patients in the New York State Multiple Sclerosis C onsortium. Multiple Sclerosis Journal, 2003, 9, 293-298.	3.0	113
59	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. NeuroImage, 2007, 36, 1294-1300.	4.2	109
60	Clinical features of children and adolescents with multiple sclerosis. Neurology, 2007, 68, S37-S45.	1.1	103
61	In vivo gene expression revealed by cDNA arrays: the pattern in relapsing–remitting multiple sclerosis patients compared with normal subjects. Journal of Neuroimmunology, 2001, 116, 213-219.	2.3	102
62	Multiple Sclerosis Therapies in Pediatric Patients With Refractory Multiple Sclerosis. Archives of Neurology, 2011, 68, 437.	4.5	101
63	Risk of bone loss in men with multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 170-175.	3.0	100
64	Clinical features of neuromyelitis optica in children. Neurology, 2016, 86, 245-252.	1.1	100
65	MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. Journal of the Neurological Sciences, 2005, 234, 17-24.	0.6	99
66	Ultrasensitive Quantification of Serum Vitamin D Metabolites Using Selective Solid-Phase Extraction Coupled to Microflow Liquid Chromatography and Isotope-Dilution Mass Spectrometry. Analytical Chemistry, 2010, 82, 2488-2497.	6.5	98
67	A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Journal, 1995, 1, 118-135.	3.0	97
68	Quercetin and interferon-β modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. Journal of Neuroimmunology, 2008, 205, 142-147.	2.3	97
69	Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1. Journal of Neuroimmunology, 1999, 93, 8-14.	2.3	95
70	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310051.	1.9	95
71	Preservation of gray matter volume in multiple sclerosis patients with the MetÂallele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Human Molecular Genetics, 2007, 16, 2659-2668.	2.9	93
72	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis Journal, 2017, 23, 1336-1345.	3.0	93

#	Article	IF	CITATIONS
73	Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. Journal of the International Neuropsychological Society, 2005, 11, 574-83.	1.8	92
74	Cost-effectiveness of disease-modifying therapy for multiple sclerosis. Neurology, 2011, 77, 355-363.	1.1	92
75	Characterizing cognitive function during relapse in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1745-1752.	3.0	92
76	Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity. Archives of Neurology, 2005, 62, 1371.	4.5	91
77	Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 722-730.	3.0	91
78	Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Multiple Sclerosis Journal, 2009, 15, 998-1005.	3.0	91
79	Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics, 2016, 138, .	2.1	89
80	Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Multiple Sclerosis Journal, 2016, 22, 1327-1336.	3.0	88
81	Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis Journal, 2013, 19, 1478-1484.	3.0	85
82	Thalamic Involvement in Multiple Sclerosis: A Diffusionâ€Weighted Magnetic Resonance Imaging Study. Journal of Neuroimaging, 2003, 13, 307-314.	2.0	84
83	Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 189-195.	1.9	84
84	Use of MR Venography for Characterization of the Extracranial Venous System in Patients with Multiple Sclerosis and Healthy Control Subjects. Radiology, 2011, 258, 562-570.	7.3	81
85	A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Multiple Sclerosis Journal, 2005, 11, 573-582.	3.0	79
86	Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 215-223.	1.3	77
87	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Medicine, 2011, 9, 22.	5.5	77
88	The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Functional Neurology, 2009, 24, 133-8.	1.3	76
89	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology, 2018, 289, 487-496.	7.3	75
90	Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Multiple Sclerosis Journal, 2010, 16, 588-596.	3.0	74

#	Article	IF	CITATIONS
91	Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study. European Journal of Vascular and Endovascular Surgery, 2012, 43, 116-122.	1.5	73
92	Regional lobar atrophy predicts memory impairment in multiple sclerosis. American Journal of Neuroradiology, 2005, 26, 1824-31.	2.4	73
93	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5â€year longitudinal study. European Journal of Neurology, 2019, 26, 87.	3.3	72
94	Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 529-534.	3.0	70
95	Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurology, The, 2008, 7, 173-183.	10.2	70
96	Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Multiple Sclerosis Journal, 2014, 20, 1502-1510.	3.0	70
97	Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. Journal of the Neurological Sciences, 2003, 209, 93-99.	0.6	69
98	MRI features of pediatric multiple sclerosis. Neurology, 2007, 68, S46-S53.	1.1	68
99	Realâ€World Effectiveness of Initial Diseaseâ€Modifying Therapies in Pediatric <scp>Multiple Sclerosis</scp> . Annals of Neurology, 2020, 88, 42-55.	5.3	68
100	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
101	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. Annals of Clinical and Translational Neurology, 2016, 3, 897-907.	3.7	67
102	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 2012, 259, 898-905.	3.6	66
103	Serum neurofilament light chain levels associations with gray matter pathology: a 5â€year longitudinal study. Annals of Clinical and Translational Neurology, 2019, 6, 1757-1770.	3.7	66
104	Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. International Journal of MS Care, 2018, 20, 9-14.	1.0	66
105	Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. International Angiology, 2010, 29, 127-39.	0.9	66
106	Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2010, 67, 1329-35.	4.5	65
107	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593.	1.1	65
108	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.2	64

#	Article	IF	CITATIONS
109	Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. American Journal of Neuroradiology, 2011, 32, 938-946.	2.4	63
110	Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology, 2016, 281, 884-895.	7.3	63
111	Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis. American Journal of Neuroradiology, 2008, 29, 319-325.	2.4	62
112	Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Multiple Sclerosis Journal, 2009, 15, 345-354.	3.0	62
113	Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis Journal, 2003, 9, 1-5.	3.0	61
114	Fatigue and Depression in Children With Demyelinating Disorders. Journal of Child Neurology, 2013, 28, 713-718.	1.4	61
115	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Multiple Sclerosis Journal, 2020, 26, 1670-1681.	3.0	61
116	Impact of diagnosis and early treatment on the course of multiple sclerosis. American Journal of Managed Care, 2013, 19, s321-31.	1.1	61
117	Iron deposition in multiple sclerosis lesions measured by susceptibilityâ€weighted imaging filtered phase: A case control study. Journal of Magnetic Resonance Imaging, 2012, 36, 73-83.	3.4	60
118	Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. NeuroImage, 2018, 167, 438-452.	4.2	60
119	What is New in the Treatment of Multiple Sclerosis?. Drugs, 2000, 59, 401-410.	10.9	59
120	Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 620-625.	1.9	58
121	Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. Journal of Neuroimmunology, 2010, 223, 92-99.	2.3	58
122	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology, 2010, 74, 538-544.	1.1	58
123	Dietary salt intake and time to relapse in paediatric multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1350-1353.	1.9	58
124	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 87-92.	2.0	58
125	Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 167-174.	2.3	57
126	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35.	0.6	56

#	Article	IF	CITATIONS
127	Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Multiple Sclerosis Journal, 2005, 11, 626-634.	3.0	55
128	Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy. American Journal of Neuroradiology, 2012, 33, 1596-1601.	2.4	55
129	Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology, 2018, 91, e1778-e1787.	1.1	55
130	Retinal nerve fiber thickness in inflammatory demyelinating diseases of childhood onset. Multiple Sclerosis Journal, 2009, 15, 802-810.	3.0	54
131	Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. International Angiology, 2010, 29, 158-75.	0.9	54
132	Multiple sclerosis gender issues: clinical practices of women neurologists. Multiple Sclerosis Journal, 2004, 10, 582-588.	3.0	52
133	Comparison of the immunomodulatory effects of the plant sterol β-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. International Immunopharmacology, 2009, 9, 153-157.	3.8	51
134	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurology, 2011, 11, 128.	1.8	50
135	Influence of Cognitive Function on Speech and Articulation Rate in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 173-180.	1.8	50
136	Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2014, 35, 106-112.	2.4	50
137	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 490-495.	2.0	50
138	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genetics, 2019, 15, e1007808.	3.5	48
139	Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Review of Neurotherapeutics, 2011, 11, 1277-1294.	2.8	47
140	Cine cerebrospinal fluid imaging in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2012, 36, 825-834.	3.4	46
141	Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis Journal, 2015, 21, 858-865.	3.0	46
142	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. The Cochrane Library, 2016, 2016, CD009333.	2.8	46
143	Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. NeuroImage, 2007, 36, 746-754.	4.2	45
144	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	4.2	45

#	Article	IF	CITATIONS
145	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	7.6	45
146	Cortical atrophy and personality in multiple sclerosis Neuropsychology, 2008, 22, 432-441.	1.3	44
147	Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers. Journal of the Neurological Sciences, 2013, 330, 71-77.	0.6	44
148	Speech and pause characteristics in multiple sclerosis: A preliminary study of speakers with high and low neuropsychological test performance. Clinical Linguistics and Phonetics, 2013, 27, 134-151.	0.9	44
149	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.4	44
150	Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2007, 187, 159-165.	2.3	43
151	Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity. Multiple Sclerosis Journal, 2008, 14, 759-763.	3.0	43
152	Randomized controlled trial of atorvastatin in clinically isolated syndrome. Neurology, 2012, 78, 1171-1178.	1.1	43
153	Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology, 2014, 83, 441-449.	1.1	43
154	Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	4.2	43
155	Cognitive Profiles of Aging in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2019, 11, 105.	3.4	43
156	TREATMENT OF FULMINANT MULTIPLE SCLEROSIS WITH INTRAVENOUS CYCLOPHOSPHAMIDE. Neurologist, 1997, 3, 178-185.	0.7	42
157	Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflammation Research, 2011, 60, 457-465.	4.0	42
158	Negative work events and accommodations in employed multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 116-119.	3.0	42
159	Benchmarks of meaningful impairment on the MSFC and BICAMS. Multiple Sclerosis Journal, 2016, 22, 1874-1882.	3.0	42
160	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.1	42
161	Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1385-1393.	3.0	42
162	Dynamics of interferon-Î ² modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-Î ² neutralizing antibodies. Journal of Neuroimmunology, 2006, 176, 125-133.	2.3	41

#	Article	IF	CITATIONS
163	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegenerative Disease Management, 2019, 9, 149-172.	2.2	41
164	HLA-DP: A Class II Restriction Molecule Involved in Epitope Spreading During the Development of Multiple Sclerosis. Human Immunology, 1998, 59, 15-24.	2.4	40
165	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS ONE, 2011, 6, e28062.	2.5	40
166	Intra- and Extraluminal Structural and Functional Venous Anomalies in Multiple Sclerosis, as Evidenced by 2 Noninvasive Imaging Techniques. American Journal of Neuroradiology, 2012, 33, 16-23.	2.4	40
167	Two decades of glatiramer acetate: From initial discovery to the current development of generics. Journal of the Neurological Sciences, 2017, 376, 255-259.	0.6	40
168	Maternal and Perinatal Exposures Are Associated With Risk for Pediatric-Onset Multiple Sclerosis. Pediatrics, 2017, 139, e20162838.	2.1	40
169	Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. American Journal of Neuroradiology, 2004, 25, 985-96.	2.4	40
170	Construct Validity and Frequency of Euphoria Sclerotica in Multiple Sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 350-356.	1.8	39
171	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e190.	6.0	39
172	Pharmacogenetics of MXA SNPs in interferon- \hat{l}^2 treated multiple sclerosis patients. Journal of Neuroimmunology, 2007, 182, 236-239.	2.3	38
173	Interferon-β treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy, 2008, 8, 1435-1447.	3.1	38
174	Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 792-801.	3.0	38
175	Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 642-647.	2.4	38
176	Recovery of cognitive function after relapse in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 71-78.	3.0	38
177	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. , 2003, 13, 307-314.		38
178	Mechanisms of interferon-β effects on bone homeostasis. Biochemical Pharmacology, 2009, 77, 1757-1762.	4.4	37
179	Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. Expert Review of Neurotherapeutics, 2016, 16, 765-775.	2.8	37
180	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	3.0	37

#	Article	IF	CITATIONS
181	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	3.0	37
182	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Human Brain Mapping, 2019, 40, 5231-5241.	3.6	37
183	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines, 2020, 8, 50.	4.4	37
184	Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis Journal, 2012, 18, 1125-1134.	3.0	36
185	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1075-1081.	1.9	36
186	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	7.3	36
187	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. Journal of Neurology, 2019, 266, 866-875.	3.6	36
188	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	3.0	35
189	Gene–environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. Journal of Neuroimmunology, 2009, 209, 123-130.	2.3	35
190	Natalizumab in pediatric multiple sclerosis patients. Therapeutic Advances in Neurological Disorders, 2010, 3, 293-299.	3.5	35
191	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
192	Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis Journal, 2006, 12, 541-550.	3.0	34
193	Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. Journal of Neuroimmunology, 2008, 205, 113-125.	2.3	34
194	The NEO-FFI in Multiple Sclerosis: Internal Consistency, Factorial Validity, and Correspondence Between Self and Informant Reports. Assessment, 2011, 18, 39-49.	3.1	34
195	Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions. CNS Drugs, 2014, 28, 731-742.	5.9	34
196	Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations. Multiple Sclerosis Journal, 2015, 21, 225-234.	3.0	34
197	Separate and Combined Influence of Cognitive Impairment and Dysarthria on Functional Communication in Multiple Sclerosis. American Journal of Speech-Language Pathology, 2018, 27, 1051-1065.	1.8	34
198	Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology, 2013, 260, 489-497.	3.6	33

#	Article	IF	CITATIONS
199	Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2015, 36, 1874-1883.	2.4	33
200	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Multiple Sclerosis Journal, 2019, 25, 1243-1254.	3.0	33
201	Aging and Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 527-535.	2.0	33
202	The neurological disease ontology. Journal of Biomedical Semantics, 2013, 4, 42.	1.6	32
203	Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis Journal, 2013, 19, 891-895.	3.0	32
204	Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. NeuroImage: Clinical, 2018, 18, 1007-1016.	2.7	32
205	Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. NeuroImage: Clinical, 2018, 17, 530-540.	2.7	32
206	Visual-cognitive processing deficits in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 449-456.	3.0	31
207	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. Journal of Vascular and Interventional Radiology, 2013, 24, 829-838.	0.5	31
208	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging, 2014, 40, 1215-1222.	3.4	31
209	Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?. Multiple Sclerosis and Related Disorders, 2015, 4, 409-413.	2.0	31
210	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. Journal of Alternative and Complementary Medicine, 2018, 24, 596-602.	2.1	31
211	Assessing â€ [~] No Evidence of Disease Activityâ€ [™] Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study. CNS Drugs, 2018 32, 75-84	5.9	31
212	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. Journal of Lipid Research, 2019, 60, 1190-1198.	4.2	31
213	Cerebellar Mutism in Pediatric Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2010, 42, 259-266.	2.1	30
214	Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology, 2019, 93, e611-e623.	1.1	30
215	Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case–control study. Clinical Nutrition, 2020, 39, 3402-3407.	5.0	30
216	Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs, 2021, 35, 743-767.	5.9	30

#	Article	IF	CITATIONS
217	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 15-28.	3.5	29
218	Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 86-91.	0.6	29
219	Fingolimod for the treatment of relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 2011, 11, 165-183.	2.8	29
220	Patterns of dietary and herbal supplement use by multiple sclerosis patients. Journal of Neurology, 2012, 259, 637-644.	3.6	29
221	Dicer and microRNA expression in multiple sclerosis and response to interferon therapy. Journal of Neuroimmunology, 2016, 292, 68-78.	2.3	29
222	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	3.7	29
223	Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS). Clinical Neuropsychologist, 2012, 26, 985-1002.	2.3	28
224	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 567-576.	3.0	28
225	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy, 2017, 17, 1163-1172.	3.1	28
226	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Multiple Sclerosis Journal, 2020, 26, 322-332.	3.0	28
227	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. Journal of Neuroimmunology, 2012, 243, 61-68.	2.3	27
228	Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS. PLoS ONE, 2015, 10, e0123771.	2.5	27
229	Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 1010-1016.	2.4	27
230	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	3.0	27
231	Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium. Multiple Sclerosis Journal, 2020, 26, 99-108.	3.0	27
232	Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron <scp>MRI</scp> . Human Brain Mapping, 2021, 42, 1463-1474.	3.6	27
233	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. Journal of Neurology, 2010, 257, 63-71.	3.6	26
234	Regression-Based Pediatric Norms for the Brief Visuospatial Memory Test – Revised and the Symbol Digit Modalities Test. Clinical Neuropsychologist, 2011, 25, 402-412.	2.3	26

#	Article	IF	CITATIONS
235	Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neuroscience, 2011, 12, 60.	1.9	26

237_	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and	0.6	26
	microstructural damage. Journal of the Neurological Sciences, 2018, 393, 128-134.		
238	Lipid profile is associated with decreased fatigue in individuals with progressive multiple sclerosis following a diet-based intervention: Results from a pilot study. PLoS ONE, 2019, 14, e0218075.	2.5	26
239	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of followâ€up. European Journal of Neurology, 2020, 27, 188.	3.3	26
240	Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. Multiple Sclerosis and Related Disorders, 2022, 57, 103433.	2.0	26
241	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. Journal of Vascular and Interventional Radiology, 2013, 24, 1487-1498.e1.	0.5	25
242	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 123-130.	2.4	25
243	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. American Journal of Neuroradiology, 2018, 39, 2237-2242.	2.4	25
244	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp> . Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	3.7	25
245	Hemostasis biomarkers in multiple sclerosis. European Journal of Neurology, 2018, 25, 1169-1176.	3.3	25
246	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. Expert Review of Neurotherapeutics, 2019, 19, 445-458.	2.8	25
247	Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. NeuroImage, 2019, 186, 308-320.	4.2	25
248	Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Current Medical Research and Opinion, 2009, 25, 2459-2470.	1.9	24
249	Treatment of multiple sclerosis in children and adolescents. Expert Opinion on Pharmacotherapy, 2010, 11, 505-520.	1.8	24
250	Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology, 2011, 18, 53-60.	2.2	24
251	Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis. Advances in Therapy, 2011, 28, 270-278.	2.9	24
252	Arterial, venous and other vascular risk factors in multiple sclerosis. Neurological Research, 2012, 34, 754-760.	1.3	24

#	Article	IF	CITATIONS
253	Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis. Psychosomatic Medicine, 2013, 75, 253-261.	2.0	24
254	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Frontiers in Bioscience - Elite, 2013, E5, 525-532.	1.8	24
255	Longitudinal personality change associated with cognitive decline in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1909-1912.	3.0	24
256	Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2018, 39, 289-295.	2.4	24
257	Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Multiple Sclerosis and Related Disorders, 2019, 34, 103-111.	2.0	24
258	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Multiple Sclerosis Journal, 2020, 26, 201-209.	3.0	24
259	Impact of Nutritional Intake on Function in People with Mild-to-Moderate Multiple Sclerosis. International Journal of MS Care, 2019, 21, 1-9.	1.0	24
260	Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Functional Neurology, 2011, 26, 205-14.	1.3	24
261	CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. International Angiology, 2010, 29, 140-8.	0.9	24
262	The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology, 2011, 18, 43-52.	2.2	23
263	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.1	23
264	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. Journal of the Neurological Sciences, 2016, 370, 13-17.	0.6	23
265	Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs, 2016, 30, 209-225.	5.9	23
266	Improved cognitive performance and event-related potential changes following working memory training in patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731774762.	1.0	23
267	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Human Brain Mapping, 2018, 39, 3682-3690.	3.6	23
268	Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Multiple Sclerosis Journal, 2022, 28, 1101-1111.	3.0	23
269	Dynamics of immune cell trafficking in interferon-Î ² treated multiple sclerosis patients. Journal of Neuroimmunology, 2003, 139, 84-92.	2.3	22
270	Combination Therapy for Multiple Sclerosis. CNS Drugs, 2004, 18, 777-792.	5.9	22

#	Article	IF	CITATIONS
271	Active Cognitive Reserve Influences the Regional Atrophy to Cognition Link in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2013, 19, 1128-1133.	1.8	22
272	Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. European Journal of Neurology, 2014, 21, 1137.	3.3	22
273	Blood circulating microparticle species in relapsing–remitting and secondary progressive multiple sclerosis. A case–control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. Journal of the Neurological Sciences, 2015, 355, 84-89.	0.6	22
274	Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatric Neurology, 2016, 57, 64-73.	2.1	22
275	Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101388.	2.0	22
276	Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. American Journal of Neuroradiology, 2019, 40, 620-625.	2.4	22
277	Serum neurofilament light chain and optical coherence tomography measures in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
278	Cognition and Physical Disability in Predicting Health-Related Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2011, 13, 57-63.	1.0	22
279	Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a. Multiple Sclerosis Journal, 2011, 17, 734-742.	3.0	21
280	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
281	The US Network of Pediatric Multiple Sclerosis Centers. Journal of Child Neurology, 2015, 30, 1381-1387.	1.4	21
282	Examining the contributions of environmental quality to pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 164-169.	2.0	21
283	Functional Connectivity and Structural Disruption in the Defaultâ€Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 523-530.	2.0	21
284	Gut microbiome is associated with multiple sclerosis activity in children. Annals of Clinical and Translational Neurology, 2021, 8, 1867-1883.	3.7	21
285	Manifestations and impact of the COVIDâ€∎9 pandemic in neuroinflammatory diseases. Annals of Clinical and Translational Neurology, 2021, 8, 918-928.	3.7	21
286	Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAs in peripheral blood mononuclear cells using DNA arrays. Drug Metabolism and Disposition, 2000, 28, 987-93.	3.3	21
287	Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. , 2003, 13, 307-14.		21
288	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs, 2022, 36, 45-59.	5.9	21

#	Article	IF	CITATIONS
289	Vitamin D and Multiple Sclerosis. Neurologist, 2012, 18, 179-183.	0.7	20
290	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	20
291	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology, 2015, 262, 326-336.	3.6	20
292	Personality traits in women with multiple sclerosis: Discrepancy in patient/partner report and disease course. Journal of Psychosomatic Research, 2009, 66, 147-154.	2.6	19
293	Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. European Journal of Neurology, 2013, 20, 1264-1271.	3.3	19
294	An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs, 2018, 32, 161-178.	5.9	19
295	Thalamic white matter in multiple sclerosis: A combined diffusionâ€ŧensor imaging and quantitative susceptibility mapping study. Human Brain Mapping, 2018, 39, 4007-4017.	3.6	19
296	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross‧ectional Structural <scp>MRI</scp> Study. Journal of Magnetic Resonance Imaging, 2021, 53, 731-739.	3.4	19
297	Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis Journal, 2000, 6, 373-377.	3.0	19
298	Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1459-1465.	3.0	18
299	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. , 2014, , CD009333.		18
300	Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. European Journal of Neurology, 2016, 23, 1101-1109.	3.3	18
301	Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2016, 22, 920-927.	1.8	18
302	Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Multiple Sclerosis Journal, 2020, 26, 1938-1947.	3.0	18
303	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087.	3.0	18
304	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. Journal of Neurology, 2021, 268, 2578-2588.	3.6	18
305	An update on new and emerging therapies for relapsing-remitting multiple sclerosis. American Journal of Managed Care, 2013, 19, s343-54.	1.1	18
306	Functional imaging during covert auditory attention in multiple sclerosis. Journal of the Neurological Sciences, 2004, 218, 9-15.	0.6	17

#	Article	IF	CITATIONS
307	Interferon Inhibitory Activity in Patients With Multiple Sclerosis. Archives of Neurology, 2006, 63, 1579.	4.5	17
308	Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer's disease. Multiple Sclerosis and Related Disorders, 2018, 22, 52-56.	2.0	17
309	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AAfatigue-metabolism nexus?. Journal of Clinical Lipidology, 2019, 13, 654-663.e1.	1.5	17
310	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. Journal of Clinical Medicine, 2019, 8, 344.	2.4	17
311	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	3.0	17
312	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	2.8	17
313	Staging and stratifying cognitive dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 463-471.	3.0	17
314	Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study. PLoS ONE, 2014, 9, e91098.	2.5	17
315	Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 157-163.	3.0	16
316	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurological Research, 2012, 34, 819-827.	1.3	16
317	Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients. NeuroImage: Clinical, 2015, 9, 110-116.	2.7	16
318	Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?. Multiple Sclerosis Journal, 2018, 24, 205-213.	3.0	16
319	Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study. Acta Neurologica Scandinavica, 2018, 138, 308-314.	2.1	16
320	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. Multiple Sclerosis and Related Disorders, 2019, 27, 298-304.	2.0	16
321	Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety, 2020, 19, 1121-1142.	2.4	16
322	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	4.4	16
323	No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1913-1917.	2.4	15
324	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology, 2012, 12, 26.	1.8	15

#	Article	IF	CITATIONS
325	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 2013, 13, 151.	1.8	15
326	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 937-943.	1.9	15
327	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. Journal of the Neurological Sciences, 2018, 388, 175-181.	0.6	15
328	Stress-full life events and multiple sclerosis: A population-based incident case-control study. Multiple Sclerosis and Related Disorders, 2018, 26, 168-172.	2.0	15
329	Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 91-98.	3.0	15
330	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102389.	2.0	15
331	Prescribing Recommendations For Interferon-Beta In Multiple Sclerosis. CNS Drugs, 1997, 8, 102-112.	5.9	14
332	Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurological Research, 2012, 34, 761-769.	1.3	14
333	The Management of Pediatric Multiple Sclerosis. Journal of Child Neurology, 2012, 27, 1384-1393.	1.4	14
334	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
335	Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. Human Brain Mapping, 2014, 35, 53-60.	3.6	14
336	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14
337	Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy, 2016, 16, 1151-1162.	3.1	14
338	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MSâ€MRIUS Study. Journal of Neuroimaging, 2017, 27, 339-347.	2.0	14
339	The Effect of Clatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing–Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs, 2018, 32, 763-770.	5.9	14
340	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 1703-1709.	2.4	14
341	Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. Journal of Comparative Effectiveness Research, 2019, 8, 305-316.	1.4	14
342	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. Neurobiology of Aging, 2020, 90, 84-92.	3.1	14

#	Article	IF	CITATIONS
343	The role of dietary antioxidant index and index of nutritional quality in MS onset: finding from an Iranian population-based incident case–control study. Nutritional Neuroscience, 2022, 25, 379-386.	3.1	14
344	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. PLoS ONE, 2011, 6, e16802.	2.5	14
345	Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e176.	6.0	13
346	Comparative efficacy of interferon \hat{l}^2 versus glatiramer acetate for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1016-1020.	1.9	13
347	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. American Journal of Neuroradiology, 2018, 39, 1480-1486.	2.4	13
348	Plasma levels of soluble NCAM in multiple sclerosis. Journal of the Neurological Sciences, 2019, 396, 36-41.	0.6	13
349	Late onset multiple sclerosis is associated with more severe ventricle expansion. Multiple Sclerosis and Related Disorders, 2020, 46, 102588.	2.0	13
350	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102653.	2.0	13
351	Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 790-800.	3.0	13
352	An association between autoreactive antibodies and anti-interferon-Î ² antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 895-899.	3.0	12
353	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	2.3	12
354	Disease progression in pediatric multiple sclerosis: disparities between physical and neurocognitive outcomes. Expert Review of Neurotherapeutics, 2011, 11, 433-440.	2.8	12
355	Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. Expert Opinion on Biological Therapy, 2014, 14, 115-126.	3.1	12
356	Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurology, 2015, 15, 232.	1.8	12
357	Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MSâ€MRIUS. Journal of Neuroimaging, 2018, 28, 399-405.	2.0	12
358	Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 245-252.	3.0	12
359	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Frontiers in Neurology, 2020, 11, 700.	2.4	12
360	Sex‧pecific Differences in Life Span Brain Volumes in Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 342-350.	2.0	12

#	Article	IF	CITATIONS
361	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
362	Clatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case–control diffusion imaging study. Pathophysiology, 2011, 18, 61-68.	2.2	11
363	Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 83, 1484-1486.	1.1	11
364	Phase White Matter Signal Abnormalities in Patients with Clinically Isolated Syndrome and Other Neurologic Disorders. American Journal of Neuroradiology, 2014, 35, 1916-1923.	2.4	11
365	MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology, 2014, 14, 131.	1.8	11
366	Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy, 2014, 3, 29-39.	3.2	11
367	Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurology, 2016, 16, 102.	1.8	11
368	Stable neuropsychiatric status in multiple sclerosis: a 3-year study. Multiple Sclerosis Journal, 2016, 22, 569-574.	3.0	11
369	Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. European Journal of Neurology, 2018, 25, 584-e36.	3.3	11
370	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis and Related Disorders, 2018, 25, 37-42.	2.0	11
371	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. Journal of Neurology, 2020, 267, 802-811.	3.6	11
372	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.1	11
373	Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years. Multiple Sclerosis Journal, 2021, 27, 1125-1135.	3.0	11
374	Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 48.	9.0	11
375	Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Review of Neurotherapeutics, 2021, 21, 353-364.	2.8	11
376	Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis. International Journal of MS Care, 1999, 1, 3-11.	1.0	11
377	Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2022, 58, 103482.	2.0	11
378	The nervous system's potential role in multiple sclerosis associated bone loss. Journal of the Neurological Sciences, 2012, 319, 8-14.	0.6	10

#	Article	IF	CITATIONS
379	MRI characteristics of familial and sporadic multiple sclerosis patients. Multiple Sclerosis Journal, 2013, 19, 1145-1152.	3.0	10
380	Is There Extra Cost of Institutional Care for MS Patients?. Multiple Sclerosis International, 2013, 2013, 1-7.	0.8	10
381	Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 830-836.	3.0	10
382	A new perspective on proxy report: Investigating implicit processes of understanding through patient–proxy congruence. Quality of Life Research, 2015, 24, 2637-2649.	3.1	10
383	mi RNA contributions to pediatricâ€onset multiple sclerosis inferred from GWAS. Annals of Clinical and Translational Neurology, 2019, 6, 1053-1061.	3.7	10
384	Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis Journal, 2020, 26, 109-113.	3.0	10
385	Diagnosis of depression in multiple sclerosis is predicted by frontal–parietal white matter tract disruption. Journal of Neurology, 2021, 268, 169-177.	3.6	10
386	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. Journal of the Neurological Sciences, 2021, 427, 117552.	0.6	10
387	Marijuana Use by Patients with Multiple Sclerosis. International Journal of MS Care, 2019, 21, 57-62.	1.0	10
388	Advances in therapy, imaging and risk factors in MS. Nature Reviews Neurology, 2012, 8, 66-68.	10.1	9
389	Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2015, 4, 228-233.	2.0	9
390	Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurology, 2015, 15, 135.	1.8	9
391	A decline in cognitive function should lead to a change in disease-modifying therapy – Yes. Multiple Sclerosis Journal, 2018, 24, 1681-1682.	3.0	9
392	<p>Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives</p> . Patient Related Outcome Measures, 2019, Volume 10, 373-384.	1.2	9
393	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. European Journal of Neurology, 2020, 27, 235-243.	3.3	9
394	Functional network dynamics and decreased conscientiousness in multiple sclerosis. Journal of Neurology, 2022, 269, 2696-2706.	3.6	9
395	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders, 2022, 57, 103406.	2.0	9
396	Gerstmann–Strässler–Scheinker syndrome masquerading multiple sclerosis. Journal of the Neurological Sciences, 2011, 309, 55-57.	0.6	8

#	Article	IF	CITATIONS
397	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurological Research, 2012, 34, 793-801.	1.3	8
398	Role of Venoplasty for Treatment of Multiple Sclerosis: Value of Open-label Studies and Surrogate Treatment Outcomes. Journal of Vascular and Interventional Radiology, 2012, 23, 1308-1310.	0.5	8
399	Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?. Neurodegenerative Disease Management, 2014, 4, 137-146.	2.2	8
400	Extracranial venous angioplasty is ineffective to treat MS. Nature Reviews Neurology, 2018, 14, 129-130.	10.1	8
401	Several household chemical exposures are associated with pediatricâ€onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	3.7	8
402	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 615-623.	2.0	8
403	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1433-1436.	3.0	8
404	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
405	Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient. Multiple Sclerosis Journal, 2021, 27, 2291-2292.	3.0	8
406	Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS ONE, 2015, 10, e0129503.	2.5	8
407	Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. Multiple Sclerosis Journal, 2022, 28, 1330-1339.	3.0	8
408	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: No. Multiple Sclerosis Journal, 2013, 19, 858-860.	3.0	7
409	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. Current Neurovascular Research, 2017, 14, 266-273.	1.1	7
410	Effect of switching from glatiramer acetate 20†mg/daily to glatiramer acetate 40†mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. Journal of the Neurological Sciences, 2018, 387, 152-156.	0.6	7
411	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. Journal of Vascular Research, 2020, 57, 16-23.	1.4	7
412	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids and Barriers of the CNS, 2020, 17, 9.	5.0	7
413	Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions. International Journal of MS Care, 2022, 24, 184-188.	1.0	7
414	New MRI criteria in the diagnosis of multiple sclerosis. Lancet Neurology, The, 2007, 6, 664-665.	10.2	6

#	Article	IF	CITATIONS
415	Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis. Journal of the Neurological Sciences, 2012, 320, 136-140.	0.6	6
416	Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. BMC Neurology, 2016, 16, 108.	1.8	6
417	No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study. Current Medical Research and Opinion, 2018, 34, 1431-1440.	1.9	6
418	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	2.5	6
419	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. Thrombosis and Haemostasis, 2019, 119, 175-178.	3.4	6
420	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Multiple Sclerosis and Related Disorders, 2019, 27, 65-73.	2.0	6
421	A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Multiple Sclerosis Journal, 2000, 6, 267-273.	3.0	6
422	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. Current Neurovascular Research, 2019, 16, 215-223.	1.1	6
423	Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis. Drug Safety, 1996, 14, 121-130.	3.2	5
424	Multiple sclerosis: predicting risk and delaying progression. Lancet Neurology, The, 2010, 9, 7-9.	10.2	5
425	Vitamin D and multiple sclerosis: can vitamin D prevent disease progression?. Expert Review of Neurotherapeutics, 2011, 11, 469-471.	2.8	5
426	Transitions between SNF and home-based care in patients with multiple sclerosis. NeuroRehabilitation, 2014, 34, 531-540.	1.3	5
427	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders 2015 & 59-70	3.5	5
428	Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report. Multiple Sclerosis and Related Disorders, 2016, 9, 54-55.	2.0	5
429	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. Journal of the Neurological Sciences, 2017, 375, 371-375.	0.6	5
430	Is Multiple Sclerosis Associated With a Lower Intraocular Pressure?. Journal of Neuro-Ophthalmology, 2017, 37, 265-267.	0.8	5
431	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over $5\hat{a}\in$ % years. BMC Neurology, 2019, 19, 121.	1.8	5
432	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. Journal of Child Neurology, 2019, 34, 148-152.	1.4	5

#	Article	IF	CITATIONS
433	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. Journal of the Neurological Sciences, 2020, 418, 117120.	0.6	5
434	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	2.7	5
435	Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 487-491.	3.0	5
436	Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple Sclerosis. International Journal of MS Care, 2017, 19, 297-302.	1.0	5
437	Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology, 2013, 13, 173.	1.8	4
438	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 553616.	2.4	4
439	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1577-1583.	2.4	4
440	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics, 2020, 10, 685.	2.6	4
441	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
442	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. Neurodegenerative Disease Management, 2021, 11, 329-340.	2.2	4
443	Impact of Cognitive Impairment and Dysarthria on Spoken Language in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2021, 27, 450-460.	1.8	4
444	Comment on "no evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onsetâ€ . Annals of Neurology, 2011, 69, 1062-1063.	5.3	3
445	Regarding CCSVI and MS: A Never-ending Story or a New Chapter?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 129-130.	1.5	3
446	No Regional Gray Matter Atrophy Differences between Pediatric―and Adultâ€Onset Relapsingâ€Remitting Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 63-67.	2.0	3
447	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing–remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. Journal of Neuroimmunology, 2015, 281, 44-50.	2.3	3
448	Medical History and Multiple Sclerosis: A Population-Based Incident Case-Control Study. Neuroepidemiology, 2019, 52, 55-62.	2.3	3
449	Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients. Diagnostics, 2020, 10, 942.	2.6	3
450	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. Multiple Sclerosis and Related Disorders, 2020, 42, 102131.	2.0	3

#	Article	IF	CITATIONS
451	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. Neurolmage: Clinical, 2021, 29, 102554.	2.7	3
452	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. NeuroImage: Clinical, 2021, 31, 102705.	2.7	3
453	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. Journal of Neurology, 2021, 268, 4796-4808.	3.6	3
454	The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102864.	2.0	3
455	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. Journal of Neuroimaging, 2021, 31, 995-1002.	2.0	3
456	Preliminary Support of a Behavioral Intervention for Trait Conscientiousness in Multiple Sclerosis. International Journal of MS Care, 2021, 24, 45-53.	1.0	3
457	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 294-300.	0.9	3
458	Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. Multiple Sclerosis Journal, 1998, 4, 480-486.	3.0	3
459	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis. Brain Imaging and Behavior, 2022, 16, 1252-1259.	2.1	3
460	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clinical Neurology and Neurosurgery, 2013, 115, S49-S54.	1.4	2
461	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. Veins and Lymphatics, 2017, 6, .	0.1	2
462	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis and Related Disorders, 2018, 22, 103-107.	2.0	2
463	Three-Day Dietary Manipulation in Multiple Sclerosis. International Journal of MS Care, 2021, 23, 199-205.	1.0	2
464	Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. Acta Neurologica Belgica, 2021, , 1.	1.1	2
465	Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). Multiple Sclerosis Journal, 2000, 6, 382-385.	3.0	2
466	Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Medica, 2012, 103, 97-102.	0.9	2
467	Unusual Long-Standing Gd-DTPA Enhancement in a Chronic Progressive Myelopathy. Journal of Computer Assisted Tomography, 1995, 19, 649-651.	0.9	1
468	Devic's disease: Diagnostic and therapeutic challenge. Multiple Sclerosis Journal, 1997, 3, 408-408.	3.0	1

#	Article	IF	CITATIONS
469	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. International Journal of Molecular Sciences, 2012, 13, 5659-5673.	4.1	1
470	Multiple sclerosis in 2019: predicting progression. Lancet Neurology, The, 2020, 19, 12-14.	10.2	1
471	Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 56, 103254.	2.0	1
472	Sensory Abnormalities in MS. International Journal of MS Care, 2004, 6, 144-147.	1.0	1
473	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis. European Radiology, 2022, , 1.	4.5	1
474	Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients. European Journal of Neurology, 2022, , .	3.3	1
475	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103906.	2.0	1
476	Management of pediatric multiple sclerosis. , 0, , 632-644.		0
477	Regarding CCSVI: Is Blinding the Key?. European Journal of Vascular and Endovascular Surgery, 2012, 43, 126.	1.5	0
478	Multiple Sclerosis Subtypes. , 2016, , 55-65.		0
479	Decrease in size of secondary neck vessels and cerebral aqueduct enlargement in multiple sclerosis: a 5-year longitudinal MRI study. Veins and Lymphatics, 2019, 8, .	0.1	0
480	Phytosterols (PS) as immunomodulators of Multiple Sclerosis (MS). FASEB Journal, 2010, 24, 332.8.	0.5	0
481	Treatment Considerations in Female MS Patients of Reproductive Age. , 2017, , 35-48.		0
482	Multiple Sclerosis and Associated Comorbidities. , 2018, , .		0
483	A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210991.	1.0	0